Sangamo Therapeutics (SGMO) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $36.1 million.
- Sangamo Therapeutics' Operating Expenses fell 682.55% to $36.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.9 million, marking a year-over-year decrease of 2621.97%. This contributed to the annual value of $161.8 million for FY2024, which is 6407.03% down from last year.
- According to the latest figures from Q3 2025, Sangamo Therapeutics' Operating Expenses is $36.1 million, which was down 682.55% from $36.2 million recorded in Q2 2025.
- Sangamo Therapeutics' 5-year Operating Expenses high stood at $139.9 million for Q1 2023, and its period low was $33.5 million during Q4 2024.
- In the last 5 years, Sangamo Therapeutics' Operating Expenses had a median value of $72.6 million in 2021 and averaged $69.8 million.
- As far as peak fluctuations go, Sangamo Therapeutics' Operating Expenses soared by 9039.22% in 2023, and later crashed by 7128.99% in 2024.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Operating Expenses stood at $67.9 million in 2021, then rose by 21.71% to $82.6 million in 2022, then decreased by 22.42% to $64.1 million in 2023, then tumbled by 47.67% to $33.5 million in 2024, then rose by 7.73% to $36.1 million in 2025.
- Its Operating Expenses was $36.1 million in Q3 2025, compared to $36.2 million in Q2 2025 and $36.1 million in Q1 2025.